C059P: Pascolizumab Biosimilar, Anti-human IL-4 Monoclonal Antibody

Catalog No.: C059P | **Product Name:** Pascolizumab Biosimilar, Anti-human IL-4 Monoclonal Antibody

The research grade pascolizumab biosimilar (anti-human anti-interleukin-4 (IL-4) monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying biological pathways affected by pascolizumab. The research grade pascolizumab biosimilar protein is for research use only (RUO).

PRODUCT SPECIFICATIONS

Catalog No.	C059P
Product Name	Pascolizumab Biosimilar, Anti-human IL-4 Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Source/Host	The anti-human Interleukin-4 (IL-4) monoclonal antibody pascolizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade pascolizumab biosimilar specifically binds to the human Interleukin-4 (IL-4).
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 0.1 EU per 1 μg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade pascolizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade pascolizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is Pascolizumab biosimilar research grade? Pascolizumab is a humanized monoclonal antibody designed for binding and neutralizing human Interleukin-4 (IL-4). Interleukin-4 plays a critical role in driving Th2-mediated immune responses, IgE class switching, and allergic inflammation. Pascolizumab biosimilar utilizes the same protein sequence as the therapeutic antibody pascolizumab to support in vitro and in vivo functional research.